ArticleOpen heart2026
Major cardiovascular events in Japanese patients with acute and chronic coronary syndrome.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular (CV) disease remains the second leading cause of mortality in Japan, yet real-world estimates of recurrent CV risk across acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) phenotypes are limited. We quantified recurrent CV risk and characterised high-risk subgroups in Japanese patients with ACS and CCS. METHODS AND
resultsThis retrospective cohort study used the Medical Data Vision claims database. Patients with ACS or CCS were followed from cohort entry to the first composite CV endpoint or end of data. The primary composite endpoint included all-cause death, myocardial infarction or stroke. The secondary composite endpoint included the primary endpoint plus hospitalisation for unstable angina, hospitalisation for heart failure or emergent or elective coronary revascularisation. Baseline clinical characteristics were evaluated as predictors. Time-to-event analyses were conducted.26 656 and 16 172 patients were included in the ACS and CCS cohorts, respectively. Median follow-up was 3.0 years in the ACS cohort and 3.2 years in the CCS cohort. The 1-year risk of the primary endpoint was 17.7% in first-time ACS, 8.0% in prior ACS and 5.3% in CCS; corresponding 5-year risks were 24.0%, 13.8% and 12.0%, respectively. In CCS, elderly men with prior ACS, heart failure, diabetes mellitus and chronic kidney disease had a 23.0% 1-year risk of the primary endpoint.
conclusionsRecurrent CV risk was highest after a first ACS event and was heterogenous in CCS, with substantially higher risk in comorbidity-burdened subgroups. These findings provide contemporary real-world estimates of recurrent CV risk and support further refinement and validation of risk-stratification approaches for secondary prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.